Roche’s Drug Candidate Meets Main Goals in Late-Stage Breast Cancer Study
PositiveHealth

Roche has announced promising results from its late-stage study of giredestrant, a drug candidate for advanced breast cancer. The combination of giredestrant and everolimus has shown a significant improvement in progression-free survival for patients, marking a potential breakthrough in treatment options. This is important as it could lead to better outcomes for those battling this challenging disease.
— Curated by the World Pulse Now AI Editorial System